Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice - PubMed (original) (raw)
Review
. 2017 Oct;33(10):1821-1831.
doi: 10.1080/03007995.2017.1335192. Epub 2017 Jun 23.
Affiliations
- PMID: 28537449
- DOI: 10.1080/03007995.2017.1335192
Review
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
Jennifer Goldman et al. Curr Med Res Opin. 2017 Oct.
Abstract
This article reviews pharmacokinetic (PK) and pharmacodynamic (PD) concepts relating to the pharmacology of basal insulin analogs. Understanding the pharmacology of currently available long-acting basal insulins and the techniques used to assess PK and PD parameters (e.g. the euglycemic clamp method) is important when considering the efficacy and safety of these agents, and can help in understanding the rationale for specific dosing strategies when tailoring therapy for a specific patient. Basal insulins such as insulin glargine 100 units (U)/mL and insulin detemir show improved PK/PD characteristics compared with the intermediate-acting NPH insulin, with a longer duration of action, a more consistent glucose-lowering effect and less prominent concentration peaks. However, more recently developed basal insulins (insulin glargine 300 U/mL, and insulin degludec 100 U/mL and 200 U/mL) have PK/PD profiles closer to the physiologic profile of endogenous basal insulin owing to a more evenly distributed, predictable and prolonged time-action profile that exceeds 24 hours and improved within-patient variability in glucose-lowering effect. The clinical implications and relevance of these PK/PD profiles is explored, including the potential effect of PK/PD parameters on glycemic control and hypoglycemia, and the timing of dosing. The improved PK/PD properties of newer longer-acting basal insulins may translate into clinical benefits for patients with type 1 and type 2 diabetes, such as more consistent insulin levels in the blood over 24 hours, lower intra-patient variability, a reduced risk of nocturnal hypoglycemia, and more flexibility in dosing time, all of which are important to consider when choosing a basal insulin regimen.
Keywords: Insulins; diabetes mellitus; pharmacodynamics; pharmacokinetics.
Similar articles
- Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR, S Bailey T, Fanelli CG, Yale JF, Bolli GB. Owens DR, et al. Diabetes Metab. 2019 Sep;45(4):330-340. doi: 10.1016/j.diabet.2018.11.004. Epub 2018 Nov 26. Diabetes Metab. 2019. PMID: 30496834 Review. - Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
Hompesch M, Patel DK, LaSalle JR, Bolli GB. Hompesch M, et al. Postgrad Med. 2019 Mar;131(2):117-128. doi: 10.1080/00325481.2019.1568136. Epub 2019 Feb 11. Postgrad Med. 2019. PMID: 30691343 Review. - Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
Vora J, Heise T. Vora J, et al. Diabetes Obes Metab. 2013 Aug;15(8):701-12. doi: 10.1111/dom.12087. Epub 2013 Mar 24. Diabetes Obes Metab. 2013. PMID: 23451796 Review. - The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
Reid TS, White J, Meneghini L. Reid TS, et al. J Fam Pract. 2019 Jan;68(1 Suppl):jfp_6801r. J Fam Pract. 2019. PMID: 30677105 - The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R, Cengiz E, Tanenberg RJ. Lajara R, et al. Curr Med Res Opin. 2017 Jun;33(6):1045-1055. doi: 10.1080/03007995.2017.1298522. Epub 2017 Mar 24. Curr Med Res Opin. 2017. PMID: 28277867 Review.
Cited by
- Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.
Shubow S, Sun Q, Nguyen Phan AL, Hammell DC, Kane M, Lyman GH, Gibofsky A, Lichtenstein GR, Bloomgarden Z, Cross RK, Yim S, Polli JE, Wang YM. Shubow S, et al. Clin Pharmacol Ther. 2023 Jan;113(1):37-49. doi: 10.1002/cpt.2765. Epub 2022 Nov 4. Clin Pharmacol Ther. 2023. PMID: 36251545 Free PMC article. Review. - Is Time-Restricted Eating Safe in the Treatment of Type 2 Diabetes?-A Review of Intervention Studies.
Uldal S, Clemmensen KKB, Persson F, Færch K, Quist JS. Uldal S, et al. Nutrients. 2022 May 30;14(11):2299. doi: 10.3390/nu14112299. Nutrients. 2022. PMID: 35684097 Free PMC article. Review. - Diurnal Variation of Real-Life Insulin Sensitivity Factor Among Children and Adolescents With Type 1 Diabetes Using Ultra-Long-Acting Basal Insulin Analogs.
Hegab AM. Hegab AM. Front Pediatr. 2022 Mar 8;10:854972. doi: 10.3389/fped.2022.854972. eCollection 2022. Front Pediatr. 2022. PMID: 35350271 Free PMC article. - Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
Vandenplas Y, Simoens S, Van Wilder P, Vulto AG, Huys I. Vandenplas Y, et al. Front Pharmacol. 2021 Apr 19;12:644187. doi: 10.3389/fphar.2021.644187. eCollection 2021. Front Pharmacol. 2021. PMID: 33953678 Free PMC article. - Glargine-300: An updated literature review on randomized controlled trials and real-world studies.
Ghosh S, Ghosh R. Ghosh S, et al. World J Diabetes. 2020 Apr 15;11(4):100-114. doi: 10.4239/wjd.v11.i4.100. World J Diabetes. 2020. PMID: 32313609 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical